36.1% of patients on new Wegovy (NOVOB DC) weight-loss pill have no prior experience on a GLP-1 drug, new study finds; Among patients on new Wegovy pill, 21.1% switched from injectable wegovy, 15.8% switched from injectable zepbound

The new study revealing that 36.1% of patients using Wegovy have no prior experience with GLP-1 drugs highlights a significant potential for market expansion beyond existing users.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

NY Fed RRP op demand at USD 1.05bln (prev. 1.45bln) across 6 counterparties (prev. 5).

Deutsche Boerse (DB1 GY) prelim FY25 (EUR): Revenue 5.2bln (exp. 6.29bln)

36.1% of patients on new Wegovy (NOVOB DC) weight-loss pill have no prior experience on a GLP-1 drug, new study finds; Among patients on new Wegovy pill, 21.1% switched from injectable wegovy, 15.8% switched from injectable zepbound

Meta (META) starts construction of USD 10bln Indiana data center

US sells USD 42bln of 10-year notes at a high yield of 4.177%, Tail 1.4bps

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This finding could bolster Novo Nordisk's market position and may drive increased interest in their product line, impacting competitor dynamics in the weight-loss pharmaceuticals sector.

Related headlines

The whole workspace, free to try.

Try it free